The expiration of the semaglutide patent will lead to generic weight-loss drugs, significantly increasing accessibility and affordability for obesity treatments in several countries, particularly India, China, and Brazil. Despite potential price reductions, concerns about misuse and the need for comprehensive obesity management strategies remain crucial, according to public health experts.













